Topics

DBV Technologies announces FDA acceptance of BLA filing for Viaskin Peanut to treat peanut allergy

05:29 EDT 7 Oct 2019 | Pharmaceutical Business Review

Viaskin Peanut is the Company’s lead product candidate designed to potentially reduce the risk of life-threatening allergic reactions due to accidental exposure to peanuts. A non-invasive, once-daily, epicutaneous

The post DBV Technologies announces FDA acceptance of BLA filing for Viaskin Peanut to treat peanut allergy appeared first on Pharmaceutical Business review.

Original Article: DBV Technologies announces FDA acceptance of BLA filing for Viaskin Peanut to treat peanut allergy

NEXT ARTICLE

More From BioPortfolio on "DBV Technologies announces FDA acceptance of BLA filing for Viaskin Peanut to treat peanut allergy"

Quick Search